{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:32:24Z","timestamp":1793291544845,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:00:00Z","timestamp":1789862400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013213","name":"ARUP Institute for Clinical and Experimental Pathology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013213","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Practical Laboratory Medicine"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.plabm.2026.e00557","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:54:14Z","timestamp":1790096054000},"page":"e00557","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Identifying and resolving analytical outliers in lipoprotein(a) immunoassay testing"],"prefix":"10.1016","volume":"52","author":[{"given":"Alexandria N.","family":"Jackson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara P.","family":"Wyness","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph W.","family":"Rudolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7219-0259","authenticated-orcid":false,"given":"Jonathan R.","family":"Genzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.plabm.2026.e00557_bib1","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Emerging Risk Factors","year":"2009","journal-title":"JAMA"},{"issue":"10459","key":"10.1016\/j.plabm.2026.e00557_bib2","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(24)01308-4","article-title":"Lipoprotein(a) and cardiovascular disease","volume":"404","author":"Nordestgaard","year":"2024","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.plabm.2026.e00557_bib3","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1161\/CIRCULATIONAHA.124.073579","article-title":"Evaluation of Lipoprotein(a) as a prognostic marker of extracoronary atherosclerotic vascular disease progression","volume":"152","author":"Bellomo","year":"2025","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.plabm.2026.e00557_bib4","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1172\/JCI115855","article-title":"Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations","volume":"90","author":"Boerwinkle","year":"1992","journal-title":"J. Clin. Investig."},{"issue":"33","key":"10.1016\/j.plabm.2026.e00557_bib5","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1093\/eurheartj\/ehy902","article-title":"High lipoprotein(a) and high risk of mortality","volume":"40","author":"Langsted","year":"2019","journal-title":"Eur. Heart J."},{"issue":"26","key":"10.1016\/j.plabm.2026.e00557_bib6","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.plabm.2026.e00557_bib7","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.plabm.2026.e00557_bib8","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/CIRCULATIONAHA.124.069210","article-title":"Lipoprotein(a) as a pharmacological target: premises, promises, and prospects","volume":"151","author":"Greco","year":"2025","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.plabm.2026.e00557_bib9","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2019","journal-title":"Eur. Heart J."},{"issue":"8","key":"10.1016\/j.plabm.2026.e00557_bib10","first-page":"1129","article-title":"2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can. J. Cardiol."},{"issue":"3","key":"10.1016\/j.plabm.2026.e00557_bib11","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1016\/j.jacl.2024.03.001","article-title":"A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice","volume":"18","author":"Koschinsky","year":"2024","journal-title":"J. Clin. Lipidol."},{"issue":"30","key":"10.1016\/j.plabm.2026.e00557_bib12","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1093\/eurheartj\/ehae191","article-title":"Eight reasons why lipoprotein(a) should be measured in everyone at least once in a lifetime","volume":"45","author":"Arsenault","year":"2024","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.plabm.2026.e00557_bib13","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.atherosclerosis.2019.12.005","article-title":"Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM","volume":"294","author":"Nordestgaard","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.plabm.2026.e00557_bib14","article-title":"Lipoprotein(a) at a \"Tipping Point\": case to move to universal screening","volume":"23","author":"Bhatia","year":"2025","journal-title":"Am. J. Prev. Cardiol."},{"key":"10.1016\/j.plabm.2026.e00557_bib15","first-page":"1","article-title":"Rationale for the routine screening of lipoprotein (a) in cardiovascular risk assessment","author":"Iatan","year":"2025","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"11 Pt 1","key":"10.1016\/j.plabm.2026.e00557_bib16","article-title":"Lipoprotein(a) testing trends in the United States 2015-2024: an analysis of 300 million individuals","volume":"4","author":"Ramsis","year":"2025","journal-title":"JACC Adv"},{"key":"10.1016\/j.plabm.2026.e00557_bib17","article-title":"Lipoprotein (a) testing patterns among subjects with a measured lipid panel: the Mayo clinic experience","volume":"20","author":"Manzato","year":"2024","journal-title":"Am. J. Prev. Cardiol."},{"issue":"21","key":"10.1016\/j.plabm.2026.e00557_bib18","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.026762","article-title":"Temporal trends in Lipoprotein(a) concentrations: the atherosclerosis risk in communities study","volume":"11","author":"Deshotels","year":"2022","journal-title":"J. Am. Heart Assoc."},{"issue":"7","key":"10.1016\/j.plabm.2026.e00557_bib19","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jacc.2021.11.055","article-title":"Repeat measures of Lipoprotein(a) molar concentration and cardiovascular risk","volume":"79","author":"Trinder","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"issue":"12","key":"10.1016\/j.plabm.2026.e00557_bib20","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/eurheartj\/ehae652","article-title":"Within-person stability of lipoprotein(a) concentration","volume":"46","author":"Ghouse","year":"2025","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.plabm.2026.e00557_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.120456","article-title":"Repeated measurement of lipoprotein(a): technical versus biological variability","volume":"409","author":"Koller","year":"2025","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.plabm.2026.e00557_bib22","unstructured":"LPA2 Tina-quant Lipoprotein(A) Gen.2. Package Insert. 2024-05, V 3.0. Roche Diagnostics. Indianapolis, IN."},{"key":"10.1016\/j.plabm.2026.e00557_bib23","series-title":"Lipoprotein(a) (Lp(a)). Hitachi 717 LP2757","year":"2016"},{"key":"10.1016\/j.plabm.2026.e00557_bib24","series-title":"Diazyme Lipoprotein(A) Assay. Package Insert. 70980 Rev. 6","year":"2024"},{"key":"10.1016\/j.plabm.2026.e00557_bib25","unstructured":"LPA2 Tina-quant Lipoprotein(A) Gen.2 Molarity. Package Insert. 2025-06, V 1.0. Roche Diagnostics. Indianapolis, IN."},{"key":"10.1016\/j.plabm.2026.e00557_bib26","unstructured":"Cobas Development Channel File Creator (CDC File Creator). Roche Diagnostics. Indianapolis, IN. https:\/\/navify.roche.com\/ch\/en-us\/marketplace\/products\/eservices\/cdc-file-creator. Accessed February 27, 2026."},{"key":"10.1016\/j.plabm.2026.e00557_bib27","series-title":"Chemical Pathology Analytical Performance Specifications","year":"2022"},{"key":"10.1016\/j.plabm.2026.e00557_bib28","article-title":"Statistics notes: what is a percentage difference?","volume":"358","author":"Cole","year":"2017","journal-title":"Br. Med. J."},{"issue":"39","key":"10.1016\/j.plabm.2026.e00557_bib29","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur. Heart J."},{"issue":"10","key":"10.1016\/j.plabm.2026.e00557_bib30","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1515\/cclm-2026-0457","article-title":"Effect of heparin plasma storage at -20 degrees C or 4 degrees C on lipoprotein(a) risk stratification","volume":"64","author":"Amesz","year":"2026","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.plabm.2026.e00557_bib33","unstructured":"Manufacturer and user facility device experience (MAUDE) database. U.S. Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfmaude\/detail.cfm?mdrfoi__id=23488026&pc=DFC&device_sequence_no=18881335. Accessed February 27, 2026."},{"issue":"2","key":"10.1016\/j.plabm.2026.e00557_bib34","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/jalm\/jfaf160","article-title":"An overview of allowable total error in the clinical laboratory","volume":"11","author":"Campbell","year":"2025","journal-title":"J. Appl. Lab. Med."},{"key":"10.1016\/j.plabm.2026.e00557_bib35","unstructured":"EFLM biological variation database. European Federation of Clinical Chemistry and Laboratory Medicine. https:\/\/biologicalvariation.eu\/\u00a0Accessed February\u00a023, 2026."},{"issue":"19","key":"10.1016\/j.plabm.2026.e00557_bib37","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1016\/j.jacc.2025.11.016","article-title":"ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"87","author":"Blumenthal","year":"2026","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.plabm.2026.e00557_bib38","unstructured":"Standardization for Lipoprotein(A) Measurements in Humans. November 19, 2019 Workshop. National Heart, Lung, and Blood Institute (https:\/\/www.nhlbi.nih.gov\/events\/2019\/standardization-lipoproteina-measurement-humans). Accessed February 25, 2026."},{"issue":"12","key":"10.1016\/j.plabm.2026.e00557_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/ph17121581","article-title":"PCSK9 inhibitors: focus on evolocumab and its impact on atherosclerosis progression","volume":"17","author":"Abduljabbar","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"issue":"11","key":"10.1016\/j.plabm.2026.e00557_bib40","doi-asserted-by":"crossref","first-page":"393","DOI":"10.31083\/j.rcm2511393","article-title":"Lipoprotein (a): underrecognized risk with a promising future","volume":"25","author":"Manzato","year":"2024","journal-title":"Rev. Cardiovasc. Med."},{"key":"10.1016\/j.plabm.2026.e00557_bib41","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.amjcard.2025.02.034","article-title":"Lipoprotein(a) - from biomarker to therapy: a review for the clinician","volume":"245","author":"Jha","year":"2025","journal-title":"Am. J. Cardiol."},{"issue":"10","key":"10.1016\/j.plabm.2026.e00557_bib42","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/phar.2851","article-title":"Role of lipoprotein(a) in atherosclerotic cardiovascular disease: a review of current and emerging therapies","volume":"43","author":"Alhomoud","year":"2023","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.plabm.2026.e00557_bib43","article-title":"Lipoprotein(a): emerging insights and therapeutics","volume":"18","author":"Kaur","year":"2024","journal-title":"Am. J. Prev. Cardiol."},{"issue":"5","key":"10.1016\/j.plabm.2026.e00557_bib44","first-page":"1208","article-title":"Pelacarsen: mechanism of action and lp(a)-lowering effect","volume":"19","author":"Bhatia","year":"2025","journal-title":"J. Clin. Lipidol."},{"issue":"3","key":"10.1016\/j.plabm.2026.e00557_bib45","doi-asserted-by":"crossref","first-page":"178","DOI":"10.2174\/011871529X418596251201142137","article-title":"Muvalaplin: a novel oral therapy for targeted reduction of plasma lipoprotein(a)","volume":"26","author":"Botros","year":"2026","journal-title":"Cardiovasc. Hematol. Disord.: Drug Targets"},{"issue":"1","key":"10.1016\/j.plabm.2026.e00557_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2024.100723","article-title":"Measuring lp(a) particles with a novel isoform-insensitive immunoassay illustrates efficacy of muvalaplin","volume":"66","author":"Swearingen","year":"2025","journal-title":"J. Lipid Res."},{"issue":"6","key":"10.1016\/j.plabm.2026.e00557_bib47","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1515\/CCLM.2004.114","article-title":"First WHO\/IFCC international reference reagent for lipoprotein(a) for Immunoassay--Lp(a) SRM 2B","volume":"42","author":"Dati","year":"2004","journal-title":"Clin. Chem. Lab. Med."},{"issue":"3","key":"10.1016\/j.plabm.2026.e00557_bib48","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/clinchem\/hvaa324","article-title":"Development of an LC-MS\/MS proposed candidate reference method for the standardization of analytical methods to measure Lipoprotein(a)","volume":"67","author":"Marcovina","year":"2021","journal-title":"Clin. Chem."},{"issue":"9","key":"10.1016\/j.plabm.2026.e00557_bib49","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1515\/cclm-2026-0130","article-title":"Analytical validation of an IFCC-endorsed mass spectrometry-based semi-automated reference measurement procedure for global standardization of serum apolipoprotein(a)","volume":"64","author":"van Neer","year":"2026","journal-title":"Clin. Chem. Lab. Med."},{"issue":"5","key":"10.1016\/j.plabm.2026.e00557_bib50","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1515\/cclm-2026-0149","article-title":"On the cusp of global lipoprotein(a) standardization","volume":"64","author":"Cobbaert","year":"2026","journal-title":"Clin. Chem. Lab. Med."}],"container-title":["Practical Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352551726000399?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352551726000399?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T15:41:32Z","timestamp":1793288492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352551726000399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":47,"alternative-id":["S2352551726000399"],"URL":"https:\/\/doi.org\/10.1016\/j.plabm.2026.e00557","relation":{},"ISSN":["2352-5517"],"issn-type":[{"value":"2352-5517","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identifying and resolving analytical outliers in lipoprotein(a) immunoassay testing","name":"articletitle","label":"Article Title"},{"value":"Practical Laboratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.plabm.2026.e00557","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"e00557"}}